Pulmonx Corp

LUNG · NASDAQ · Healthcare / Medical Devices

2.86USD-0.14 (-4.67%)

Price History

Full chart

Market Stats

Previous Close3.00

Open2.99

Day Range2.78 – 3.04

52-Week Range1.13 – 2.89

Volume695.07K

Market Cap82.78M

P/E (TTM)0.00

Forward P/E28.33

EPS-1.15

Dividend Yield0.00%

Beta0.34

50-Day Avg1.98

200-Day Avg1.69

About

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Company Details

SectorHealthcare
IndustryMedical Devices
CEOMr. Glendon E. French
Employees296
Headquarters700 Chesapeake Drive, Redwood City, CA, United States, 94063, USA
Websitehttps://pulmonx.com

Leadership

Mr. Glendon E. FrenchCEO, President & Director · b. 1962
Dr. Derrick Sung Ph.D.CFO & COO · b. 1973
Mr. David A. Lehman J.D.General Counsel & Secretary · b. 1961
Mr. Srikanth RadhakrishnanChief Science & Technology Officer · b. 1973
Ms. Marcee M. MaroneyVice President of Marketing · b. 1970
Mr. Jérôme ErathSenior VP & GM of International
Mr. Geoffrey Beran RoseChief Commercial Officer · b. 1974
Dr. Narinder S. Shargill Ph.D.Senior Vice President of Global Medical & Clinical Affairs · b. 1955
Mr. John B. McKuneVP of Finance & Corporate Controller · b. 1976

Financials

Income Statement

Currency: USD	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	115.00K	332.00K	19.45K	8.80K	0	20.00M	32.59M	32.73M	48.42M	53.66M	68.67M	83.79M	90.50M
Growth (%)	-	+188.70%	-94.14%	-54.76%	-100.00%	-	+62.94%	+0.42%	+47.91%	+10.84%	+27.98%	+22.01%	+8.01%
Cost of Revenue	0	48.82K	15.56K	10.19K	0	7.72M	10.18M	11.53M	12.79M	13.80M	17.92M	21.79M	23.36M
Gross Profit	115.00K	283.18K	3.89K	-1.39K	0	12.29M	22.41M	21.20M	35.63M	39.87M	50.75M	62.00M	67.14M
Gross Margin	100.00%	85.29%	19.98%	-15.83%	-	61.42%	68.77%	64.77%	73.59%	74.29%	73.90%	74.00%	74.19%
Operating Expense	1.06M	2.00M	2.51M	2.51M	5.25M	27.34M	40.25M	53.53M	82.93M	98.50M	112.69M	119.70M	120.80M
Operating Income	-942.34K	-1.72M	-2.50M	-2.51M	-5.25M	-15.05M	-17.84M	-32.33M	-47.30M	-58.64M	-61.94M	-57.70M	-53.66M
Operating Margin	-819.43%	-517.18%	-12876.06%	-28517.52%	-	-75.24%	-54.73%	-98.77%	-97.70%	-109.27%	-90.19%	-68.87%	-59.30%
EBITDA	-	-	-	-	-	-15.68M	-16.82M	-28.44M	-46.62M	-55.99M	-55.09M	-50.79M	-49.17M
EBITDA Margin	-	-	-	-	-	-78.37%	-51.61%	-86.88%	-96.29%	-104.34%	-80.22%	-60.62%	-54.33%
Net Income	-1.23M	-1.92M	-2.80M	-2.78M	-5.37M	-18.48M	-20.70M	-32.23M	-48.66M	-58.92M	-60.84M	-56.39M	-54.00M
Net Income Margin	-1072.14%	-579.35%	-14398.30%	-31539.27%	-	-92.38%	-63.52%	-98.47%	-100.51%	-109.80%	-88.60%	-67.30%	-59.67%
R&D	798.39K	610.20K	1.25M	1.22M	1.63M	6.99M	6.05M	7.46M	13.06M	15.40M	18.08M	17.57M	19.49M
R&D as % of Total Revenue	694.25%	183.79%	6430.45%	13854.42%	-	34.95%	18.56%	22.79%	26.98%	28.69%	26.33%	20.97%	21.54%
Interest Expense	0	0	0	0	0	2.52M	2.32M	3.18M	829.00K	1.07M	3.23M	3.51M	3.15M
Interest Expense % of Total Revenue	0.00%	0.00%	0.00%	0.00%	-	12.60%	7.11%	9.72%	1.71%	1.99%	4.71%	4.19%	3.49%

Balance Sheet

Currency: USD	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	104.99K	473.73K	1.01M	577.97K	1.47M	15.01M	53.53M	263.71M	235.17M	193.68M	177.78M	162.85M	129.29M
Total Liabilities	1.88M	1.89M	3.66M	3.41M	1.53M	182.34M	240.91M	37.57M	41.93M	39.67M	59.47M	77.04M	75.17M
Total Equity	-1.78M	-1.41M	-2.65M	-2.84M	-63.18K	-167.33M	-187.38M	226.13M	193.24M	154.01M	118.31M	85.81M	54.12M
Cash	87.08K	4.04K	451.53K	28.92K	636.64K	4.12M	14.77M	231.79M	148.48M	101.74M	83.55M	70.91M	70.01M
Total Debt	-	-	-	-	-	33.60M	227.15M	27.22M	26.46M	24.40M	41.42M	56.47M	56.36M
Net Debt	-	-	-	-	-	29.48M	212.39M	-204.57M	-122.02M	-77.33M	-42.12M	-14.43M	-13.64M

Cash Flow

Currency: USD	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-811.78K	-1.34M	-2.56M	-2.03M	-4.64M	-18.39M	-20.77M	-30.63M	-41.43M	-45.14M	-37.61M	-31.54M	-32.45M
Investing Cash Flow	-1.01K	-63.15K	-164.49K	-26.80K	-26.80K	200.00K	-14.23M	12.69M	-46.26M	-4.22M	-2.01M	17.48M	30.48M
Financing Cash Flow	897.00K	1.32M	3.17M	1.61M	5.27M	12.11M	45.62M	234.83M	4.50M	2.47M	21.40M	1.36M	903.00K
Capital Expenditure	1.01K	63.15K	164.49K	27.20K	27.20K	316.00K	720.00K	911.00K	3.67M	1.32M	807.00K	1.45M	452.00K
Free Cash Flow	-	-	-	-	-	-18.71M	-21.48M	-31.54M	-45.10M	-46.45M	-38.42M	-32.98M	-32.90M
Dividends Paid	-	-	-	-	-	-	46.19M	21.00K	-	-	21.40M	-	-
FCF to OCF	-	-	-	-	-	101.72%	103.47%	102.97%	108.86%	102.92%	102.15%	104.59%	101.39%
Dividend Paid to FCF	-	-	-	-	-	-	-214.97%	-0.07%	-	-	-55.70%	-	-

Earnings

Report Date	Jan 28, 2020	Sep 4, 2020	Nov 10, 2020	Mar 2, 2021	May 4, 2021	Aug 3, 2021	Nov 2, 2021	Feb 23, 2022	May 3, 2022	Aug 2, 2022	Nov 3, 2022	Feb 22, 2023	May 2, 2023	Aug 2, 2023	Oct 30, 2023	Feb 21, 2024	May 1, 2024	Jul 31, 2024	Oct 30, 2024	Feb 19, 2025	Apr 30, 2025	Jul 30, 2025	Nov 12, 2025	Feb 25, 2026	Apr 29, 2026	Jul 29, 2026	Nov 11, 2026
EPS Estimate	0.00	0.00	-5.33	-0.28	-0.37	-0.37	-0.38	-0.36	-0.36	-0.41	-0.40	-0.42	-0.45	-0.44	-0.43	-0.41	-0.46	-0.43	-0.45	-0.45	-0.40	-0.40	-0.42	-0.39	-0.33	-0.28	-0.26
EPS Actual	-0.02	-5.93	-2.27	-0.27	-0.34	-0.34	-0.28	-0.35	-0.43	-0.40	-0.38	-0.38	-0.42	-0.43	-0.39	-0.36	-0.36	-0.35	-0.36	-0.33	-0.36	-0.38	-0.34	-0.25	-0.33	-0.24	-
Surprise	-	-	57.41%	3.57%	8.11%	8.11%	26.32%	2.78%	-19.44%	2.44%	5.00%	9.52%	6.67%	2.27%	9.30%	12.20%	21.74%	18.60%	20.00%	26.67%	10.00%	5.00%	19.05%	36.68%	0.00%	14.29%	-
Timing	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	-	After-hours	After-hours	After-hours

Key Statistics & Ratios

Market Cap82.78M

Enterprise Value86.91M

Trailing P/E0.00

Forward P/E28.33

Price / Sales0.96

Price / Book2.21

EPS-1.15

Book Value0.913

Revenue (TTM)87.44M

Gross Profit (TTM)67.38M

EBITDA-45.49M

Profit Margin-55.03%

Operating Margin-39.80%

Return on Equity-88.87%

Return on Assets-22.10%

Shares Outstanding42.24M

Shares Float37.61M

Beta0.34

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Analyst Ratings

Buy

Based on 7 analystsTarget 3.40

Strong Buy
4
Buy
1
Hold
2

Ownership Breakdown

Institutions: 62.81%
Insiders: 4.64%
Retail / Other: 32.55%

Top Institutional Holders

PRIMECAP Management Company
4.61M10.74%
Morgan Stanley - Brokerage Accounts
3.99M9.30%
Soleus Capital Management, L.P.
2.79M6.49%
BlackRock Inc
2.66M6.20%
ExodusPoint Capital Management, LP
1.94M4.53%
Vanguard Capital Management, LLC
1.63M3.81%
Bank of America Corp
1.17M2.72%
Deutsche Bank AG
1.16M2.71%
Geode Capital Management, LLC
944.49K2.20%
State Street Corp
809.12K1.88%
Stonepine Capital Management Llc
768.29K1.79%
BRAIDWELL LP
752.54K1.75%
Barclays PLC
683.43K1.59%
Parkman Healthcare Partners LLC
646.56K1.51%
Vanguard Portfolio Management, LLC
604.46K1.41%

Top Fund Holders

PRIMECAP Odyssey Aggressive Growth
3.60M8.39%
Vanguard MStar Total Stk Mkt Idx Invest
1.15M2.68%
Xtrackers S&P 500 Swap ETF 1C
692.75K1.61%
Vanguard US Opportunities Ins USD Acc
554.13K1.29%
Xtrackers S&P Global Infra Swap ETF 1C
402.32K0.94%